The prediction antidepressant effects of Chai-Hu-Jia-Long-Gu-Mu-Li decoction by Arrowsmith tool

Background:To explore the modern pharmacological mechanism of classic ancient prescription of Chinese medicine Chai-Hu-Jia-Long-Gu-Mu-Li decoction and single drug in classic ancient prescription of Chinese medicine Chai-Hu-Jia-Long-Gu-Mu-Li decoction on antidepressant from the theoretical level.Methods:The literature related search tool Arrowsmith was used with the help of Cytoscape drawing software,the relationship between classic ancient prescription of Chinese medicine Chai-Hu-Jia-Long-Gu-Mu-Li decoction and the antidepressant mechanism was analyzed.Results:Different single drugs in classic ancient prescription of Chinese medicine Chai-Hu-Jia-Long-Gu-Mu-Li decoction may play an antidepressant effect by regulatingβ-catenin,toll-like receptor 4,brain-derived neurotrophic factor,caspase-3,γ-aminobutyric acid A receptor,MAPK,Akt,ERK,AMPK,Wnt,STAT3,CREB,NMDA,iNOS,PKA,matrix metalloproteinase-9,IL-10,ApoE,P38 MAPK,MMP-2,AMPA,PPARγ,TNFα,NF-κB,TGF,CaMKII and EPO.The key antidepressant site is in the hippocampus.Conclusion:The antidepressant effect of classic ancient prescription of Chinese medicine Chai-Hu-Jia-Long-Gu-Mu-Li decoction reflects the action characteristics of multi-components,multi-targets,and multi-pathways of traditional Chinese medicine.Through the search and analysis by Arrowsmith tools,it provides a scientific basis for in-depth interpretation of the antidepressant mechanism and provides research direction and ideas for the research of traditional Chinese medicine compound prescription.

Clinical observation of Shengxuebao Mixture in treating anemia after concurrent chemoradiotherapy for cervical cancer

Objective:To investigate the efficacy of the Shengxuebao Mixture in treating anemia after concurrent chemoradiotherapy for cervical cancer.Methods:The patients who met the criteria were randomly divided into the study group(n=30)and the control group(n=30).The study group was treated with Shengxuebao Mixture(15 ml once,three times a day)for 30 days,and the control group was treated with ferrous succinate tablets(0.1 g,twice a day),folic acid tablets(5 mg,three times a day),and vitamin B12 tablets(25μg,once a day)for 30 days.Observed the hemoglobin level,erythropoietin level,TCM syndrome score,karnofsky performance status score before and after treatment in the two groups,compared the relevant data and clinical efficacy between the two groups and observed the adverse drug reactions at the same time.Results:The age,pathological type,stage,baseline hemoglobin level,erythropoietin level,TCM syndrome score,and karnofsky performance status score were comparable between the two groups(P>0.05).The hemoglobin level of the two groups after treatment was higher than before treatment(P<0.05).After treatment,the hemoglobin level in the study group was significantly higher than that in the control group(P<0.05),and the number of effective cases in the study group was more than that in the control group,and the effective rate in the study group was higher than that in the control group(P<0.05).The erythropoietin level of the two groups after treatment was lower than before treatment(P<0.05).After treatment,the erythropoietin level in the study group was significantly lower than that in the control group(P<0.05).The TCM syndrome score of the study group decreased significantly after treatment(P<0.05),but there was no significant change in the control group(P>0.05).After treatment,the TCM syndrome score of the study group was significantly lower than that of the control group(P<0.05),and the number of effective cases in the study group was more than that in the control group,and the effective rate in the study group was higher than that in the control group(P<0.05).There was no significant change in the karnofsky performance status score of the study group after treatment(P>0.05),but the karnofsky performance status score of the control group decreased significantly(P<0.05).After treatment,the karnofsky performance status score of the study group was higher than that of the control group(P<0.05),and the number of effective cases in the study group was more than that of the control group,and the effective rate was higher than that of the control group(P<0.05).And there were no obvious adverse reactions in this study.Conclusion:To some extent,this study showed that the Shengxuebao Mixture has a definite effect in treating anemia after concurrent chemoradiotherapy for cervical cancer,can promote the use of erythropoietin,improve TCM syndromes and stabilize the quality of life of patients.

Progress research on non-drug therapy in cancer-related fatigue

Cancer-related fatigue is the most prevalent and persistently symptom in cancer survivors than any other symptom,which is caused by both the disease and its treatment.Patients with cancer show a severe symptom of fatigue,which cannot be relieved by general rest or sleep.Cancer-related fatigue negatively impacts a patient's physical and emotional function,social ability and even patients’prognosis.At present,the mechanism of cancer-related fatigue remain unclear despite much research,and a variety of mechanisms may contribute to its occurrence and development,including inflammatory reaction,metabolism dysregulation,immune activation,hormonal changes,central nervous system dysfunction,etc.Now a broad variety of drugs and non-drugs interventions are used against cancer-related fatigue.The intervention of conventional western medicine mainly contains hematopoietic stimulants,hormones,mental stimulants,and antidepressants,but their widely clinical application is limited by their effectiveness and possible side effects to a certain degree.There are also many forms of non-drug interventions for managing cancer-related fatigue,such as exercise intervention,psychological intervention,sleep intervention,nutrition intervention,bright white light therapy,etc.The aim of this review is to provide recommendations of non-drug interventions for patients with CRF during and after cancer treatment,in order to provide an evidence-based guideline for clinicians.